Samoel Ashimosi Khamadi

Dr. Samoel Ashimosi Khamadi

Centre for Virus Research, Kenya Medical Research Institute, KEMRI, Nairobi, Nairobi City, Kenya
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2013 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
BMBeatrice Mukami Muriuki
Beatrice Mukami Muriuki
MGMichael Muita Gicheru
Michael Muita Gicheru
DWDorcas Wachira
Dorcas Wachira
ANAnthony Kebira Nyamache
Anthony Kebira Nyamache
Samoel Ashimosi KhamadiSamoel Ashimosi Khamadi
Samoel Ashimosi Khamadi
Background: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-infections among HIV-1 infected individuals are growing worldwide health problems characterized by lack of effective vaccines, need for expensive treatment, chronicity of morbidity and associated mortality. Their prevalence and distribution patterns continue to vary across geographical locations with high prevalence being detected among high risk populations. To determine the prevalence of HBV and HCV among HIV-1 infected individuals, blood samples were collected from consenting study subjects visiting comprehensive HIV clinics in Nairobi during the period between October and December 2009.Methods: Blood samples from volunteers were screened with ELISA tests for detecting HIV, HBV surface antigen (HBsAg) and anti-HCV antibodies.Results: In a total of three (300) hundred infected individuals consisting of 129 (43%) males and 171 (57%) females 15.3% (46/300) were HIV-1 co-infected with either HBV or HCV or both, 10.3% (31/300) with HIV-1 and HCV and 6% (18/300) with HIV-1 and HBV infections. However, only three individuals (1%) were coinfected with the three viruses (HIV/HBV/HCV).Conclusion: Though, low levels of co-infection with all three viruses were reported, there could be higher prevalence rates than reported here especially among high risk populations.

1 February 2012 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
SKSheila Kageha
Sheila Kageha
RLRaphael W. Lihana
Raphael W. Lihana
VOVincent Okoth
Vincent Okoth
MMMatilu Mwau
Matilu Mwau
FOFredrick A. Okoth
Fredrick A. Okoth
Samoel Ashimosi KhamadiSamoel Ashimosi Khamadi
Samoel Ashimosi Khamadi
Human immunodeficiency virus 1 (HIV-1) infection is characterized by genetic diversity such that specific viral subtypes are predominant in specific geographic areas. To determine circulating subtypes of HIV-1 in different parts of central Kenya, a cross-sectional study was carried out on HIV-1-positive blood samples collected from consenting individuals in eight hospitals of Kenya's central province. Proviral DNA was extracted from peripheral blood mononuclear cells. Polymerase chain reaction and direct sequencing using primers generated from a highly conserved region of HIV-1 env gp41 were carried out. Ninety-six samples were successfully amplified and sequenced. Analysis of the sequences showed that a majority of them belonged to subtype A1 (67/96, 69.8%), followed by subtypes D (18, 18.7%) and C (11/96, 11.5%). Consistent with findings in other parts of Kenya, HIV-1 subtype A1 was the most dominant virus in circulation. Continued surveillance of circulating subtypes of HIV-1 in Kenya is important in determining the evolution of the HIV/AIDS epidemic in Kenya.

1 January 2013 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
EBErick M Bosire
Erick M Bosire
ANAnthony K Nyamache
Anthony K Nyamache
MGMichael M Gicheru
Michael M Gicheru
Samoel Ashimosi KhamadiSamoel Ashimosi Khamadi
Samoel Ashimosi Khamadi
RLRaphael W Lihana
Raphael W Lihana
VOVincent Okoth
Vincent Okoth
The enumeration of absolute CD4 counts is of primary importance for many medical conditions especially HIV infection where therapeutic initiation depends on the count. These ranges tend to vary across populations. However, these ranges have not been comprehensively established in the Kenyan population. Therefore, this study aimed at establishing the reference ranges for the CD4 and CD8 T-lymphocytes in normal healthy individuals in Kenya.

24 February 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
SOSilvanos M. Opanda
Silvanos M. Opanda
FWFred Wamunyokoli
Fred Wamunyokoli
Samoel Ashimosi KhamadiSamoel Ashimosi Khamadi
Samoel Ashimosi Khamadi
RCRodney Coldren
Rodney Coldren
WBWallace Bulimo
Wallace Bulimo
Enteroviruses (EV) are responsible for a wide range of clinical diseases in humans. Though studied broadly in several regions of the world, the genetic diversity of human enteroviruses (HEV) circulating in the sub-Saharan Africa remains under-documented. In the current study, we molecularly typed 61 HEV strains isolated in Kenya between 2008 and 2011 targeting the 3′-end of the VP1 gene. Viral RNA was extracted from the archived isolates and part of the VP1 gene amplified by RT-PCR, followed by sequence analysis. Twenty-two different EV types were detected. Majority (72.0 %) of these belonged to Enterovirus B species followed by Enterovirus D (21.3 %) and Enterovirus A (6.5 %). The most frequently detected types were Enterovirus-D68 (EV-D68), followed by Coxsackievirus B2 (CV-B2), CV-B1, CV-B4 and CV-B3. Phylogenetic analyses of these viruses revealed that Kenyan CV-B1 isolates were segregated among sequences of global CV-B1 strains. Conversely, the Kenyan CV-B2, CV-B3, CV-B4 and EV-D68 strains generally grouped together with those detected from other countries. Notably, the Kenyan EV-D68 strains largely clustered with sequences of global strains obtained between 2008 and 2010 than those circulating in recent years. Overall, our results indicate that HEV strains belonging to Enterovirus D and Enterovirus B species pre-dominantly circulated and played a significant role in pediatric respiratory infection in Kenya, during the study period. The Kenyan CV-B1 strains were genetically divergent from those circulating in other countries. Phylogenetic clustering of Kenyan EV-D68 strains with sequences of global strains circulating between 2008 and 2010 than those obtained in recent years suggests a high genomic variability associated with the surface protein encoding VP1 gene in these enteroviruses.

30 December 2009 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
RLRaphael W Lihana
Raphael W Lihana
Samoel Ashimosi KhamadiSamoel Ashimosi Khamadi
Samoel Ashimosi Khamadi
RLRaphael M Lwembe
Raphael M Lwembe
JKJoyceline G Kinyua
Joyceline G Kinyua
JMJoseph K Muriuki
Joseph K Muriuki
ESElijah M Songok
Elijah M Songok
Infection with HIV-1 is characterized by genetic diversity such that specific viral subtypes are predominant in specific geographical areas. The genetic variation in HIV-1 pol and env genes is responsible for rapid development of resistance to current drugs. This variation has influenced disease progression among the infected and necessitated the search for alternative drugs with novel targets. Though successfully used in developed countries, these novel drugs are still limited in resource-poor countries. The aim of this study was to determine HIV-1 subtypes, recombination, dual infections and viral tropism of HIV-1 among Kenyan patients prior to widespread use of antiretroviral drugs.

28 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
CWCAROLYNE NASIMIYU WANYONYI
CAROLYNE NASIMIYU WANYONYI
INIsaac Ambogo Ngere
Isaac Ambogo Ngere
JDJeanette Dawa
Jeanette Dawa
PAPatrick Amoth
Patrick Amoth
OOOuma Oluga
Ouma Oluga
MNM. Kariuki Njenga
M. Kariuki Njenga
Considering the early inequity in global COVID-19 vaccine distribution, we compared the level of population immunity to SARS-CoV-2 with vaccine uptake and refusal between rural and urban Kenya two years after the pandemic onset. A population-based seroprevalence study was conducted in the city of Nairobi (n = 781) and a rural western county (n = 810) between January and February 2022. The overall SARS-CoV-2 seroprevalence was 90.2% (95% CI, 88.6–91.2%), including 96.7% (95% CI, 95.2–97.9%) among urban and 83.6% (95% CI, 80.6–86.0%) among rural populations. A comparison of immunity profiles showed that >50% of the rural population were strongly immunoreactive compared to 75%), inadequate information (26%), and concern about vaccine effectiveness (9%). Less than 2% of vaccine refusers cited religious or cultural beliefs. These findings indicate that despite vaccine inequity, hesitancy, and refusal, herd immunity had been achieved in Kenya and likely other African countries by early 2022, with natural infections likely contributing to most of this immunity. However, vaccine campaigns should be sustained due to the need for repeat boosters associated with waning of SARS-CoV-2 immunity and emergence of immune-evading virus variants.